(Nanatinostat + valganciclovir) is under clinical development by Viracta Therapeutics and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData, Phase II drugs for Peripheral T-Cell Lymphomas (PTCL) have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Nanatinostat + valganciclovir)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Nanatinostat + valganciclovir) overview
Nana-Val is under development for the treatment for EBV-associated cancers including solid tumors like nasopharyngeal carcinoma, plasmablastic lymphoma, gastric cancer, nasopharyngeal cancer, colon cancer, natural killer cell lymphomas, peripheral T-cell lymphomas (PTCL), gastric carcinoma, leiomyosarcoma, sarcoma, angioimmunoblastic T-cell lymphoma, lymphoepithelioma, post-transplant lymphoproliferative disorder, cutaneous T cell lymphoma, diffuse large B cell lymphoma, systemic lupus erythematosus, latent viral infections and Hodgkin lymphoma. It is a small molecule administered orally. It is a combination of nanatinostat and valganciclovir. The drug is developed based on Esterase Sensitive Motif (ESM) technology. Nanatinostat acts by targeting HDAC and valganciclovir acts by targeting DNA polymerase.
It was also under development for the treatment of solid tumor and relapsed/refractory multiple myeloma.
Viracta Therapeutics overview
Viracta Therapeutics, develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company’s pipeline products include Nana-val for the treatment of Lymphoma and Solid Tumors; SSN-510 for the treatment of hematology and solid tumors. The company had partnered programs under development include TAK-580 (formerly MLN2480) and Vosaroxin for the treatment of various types of cancer. The company entered into partnership with Biogen, Takeda, DOT Therapeutics-1, Inc, Denovo Biopharma, LLC for the development of pipeline products. Viracta is headquartered in Cardiff, California, the US.
For a complete picture of (Nanatinostat + valganciclovir)’s drug-specific PTSR and LoA scores, buy the report here.